Summary
Boston Scientific Corporation (BSX) reported its first-quarter 2001 financial results, showing a net loss of $5 million, or $0.01 per share, a significant decline from the $106 million profit, or $0.26 per share, in the same quarter last year. This downturn was largely attributed to a substantial $79 million charge for purchased research and development related to recent acquisitions, as well as restructuring costs associated with a global operations plan. Despite a 4% reported decline in net sales to $654 million, primarily impacted by foreign currency fluctuations and a challenging coronary stent market, the company made strategic moves by completing three key acquisitions: Embolic Protection, Inc., Catheter Innovations, Inc., and Quanam Medical Corporation. These acquisitions aim to broaden the company's product portfolio in growth areas. Management is focused on integrating these new entities, optimizing its global operations, and navigating a competitive landscape, while also managing ongoing litigation.
Key Highlights
- 1Reported a net loss of $5 million ($0.01/share) for Q1 2001, compared to a net income of $106 million ($0.26/share) in Q1 2000.
- 2Net sales decreased by 4% to $654 million, impacted by $24 million in foreign currency fluctuations.
- 3Recorded a significant $79 million charge for purchased research and development related to three acquisitions completed in the quarter.
- 4Completed acquisitions of Embolic Protection, Inc., Catheter Innovations, Inc., and Quanam Medical Corporation to expand product offerings.
- 5Launched a global operations plan, including a plant optimization initiative, which incurred $13 million in costs during the quarter and is expected to yield significant savings.
- 6Worldwide coronary stent revenues declined to $100 million from $113 million in the prior year's quarter.
- 7The company is actively involved in numerous patent litigation cases, with a significant potential liability related to a jury verdict in a Johnson & Johnson patent infringement case.